---

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2014

					(Rupees in '000')
S. No.	Particulars		Un -audited		Audited
			Quarter Ended		Year Ended
			30.06.2014	31.03.2014	30.06.2013	31.03.2014
PART - I
1	(a) Income from Operation
		Gross Sales	22,278	18,213	20,712	77,960
		Less: Excise Duty	757	237	1,398	3,932
	Net Sales		21,521	17,976	19,314	74,028
	(b) Other Operating  Income		-	-	-	-
	Total Income from Operation		21,521	17,976	19,314	74,028
2	Expenditure		-	-	-	-
	(a)	Consumption of Materials	4,730	409	6,601	18,048
	(b)	Purchase of Goods Traded	6,440	6,651	1,777	13,275
	(c)	(Increase)/Decrease in stock in trade	(787)	1,785	15	>2,012
	(d)	Staff Cost	6,555	5,758	6,212	25,313
	(e)	Depreciation	655	656	655	2,624
	(f)	Other Expenditure	3,262	2,587	3,397	11,923
	Total Expenditure		20,855	17,846	18,657	73,195
3	Profit /Loss from Operation Before Other Income (1-2)		666	130	657	833
4	Other  Income /(Loss)		58	287	51	1,273
5	Profit /Loss before Interest & Exceptional items (3+4)		724	417	708	2,106
6	Interest		226	(125)	405	841
7	Profit /Loss  after Interest but before exceptional items (5-6)		498	542	303	1,265
8	Exceptional items		-	-	-	-
9	Profit /Loss before Tax (7-8)		498	542	303	1,265
10	Tax Expenses (Provision for Taxation): Current tax		(60)	-	-	229
		Deffered tax	(75)	-	-	371
11	Net Profit/Loss  after Tax (9-10)		363	542	303	665
12	Paid up Equity Share Capital (Face Value 10/- Per Share)		354,35	354,35	354,35	354,35
	[Net of allotment money in arrears]
13	Reserves Excluding Revaluation Reserves		-	-	-	9,093
14	Earning per share (EPS) before extraordinary item (not Annualised)		-	-	-	-
	Basic & Diluted		-	-	-	0.15
PART-II	A. PARTICULARS  OF SHAREHOLDING
1	Public Shareholding
	i)	Number of Shares	28,94,901	28,94,901	29,04,901	28,94,901
	ii)	Percentage of shareholding	63.33%	63.33%	63.55%	63.33%
2	Promoters and promoter group Shareholding
	a)	Pledged/Encumbered
	i)	Number of shares	-	-	-	-
	ii)	Percentage of shares (as a % of the total shareholding of	-	-	-	-
		promoter and promoter group)
	iii)	Percentage of shares (as a% of the total share capital of the company)	-	-	-	-
	b)	Non-encumbered
	i)	Number of Shares	16,76,099	16,76,099	16,66,099	16,76,099
	ii)	Percentage of shares (as a% of the total shareholding)	36.67%	36.67%	36.45%	36.67%
		of promoter and promoter group)
	iii)	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%

 

	B. INVESTORS COMPLAINTS		3 Months ended 30.06.14
	Pending at Begining of the Quarter		NIL
	Received During the Quarter		NIL
	Disposed of During the Quarter		NIL
	Remaining at the end of the Quarter		NIL

 

NOTES :-

1. Theabove financial results have been taken on record at a meeting of Board of Directors held on 31-07-2014. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable. Previous period figures have been regrouped wherever required.

 

	For and on behalf of the Board
	COLINZ LABORATORIES LIMITED
Mumbai	Dr. L. S. Mani
31.07.2014	Chairman & Managing Director.

                                                                                                                     

(Top)